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Liquid based cytology in cervical cancer screening
Is as sensitive as conventional cytology, and has other advantages
Cervical screening has been shown to reduce the 
incidence of cervical cancer, but only in the setting of 
well organised, high quality programmes. In the United 
Kingdom the NHS cervical screening programme has 
been estimated to prevent around 80% of deaths from 
cervical cancer.1
Liquid based cytology represents the first major change 
in preparation method for cervical screening samples for 
over 50 years. Instead of cells being smeared onto a glass 
slide, they are washed into a vial of liquid and filtered, 
and a random sample is presented in a thin layer on a 
glass slide. These slides can then either be screened by 
skilled staff or subjected to partially automated imaging. 
The process is being widely used in the United States, 
many European countries, and elsewhere.
In this week’s BMJ two studies compare the accuracy 
of liquid based cytology with conventional cytology.2 3 
The randomised trial by Ronco and colleagues found 
no significant difference in sensitivity for cervical 
intraepithelial neoplasia of grade 2 or more with liquid 
based cytology using ThinPrep (Cytyc, Boxborough, 
MA, USA) compared with conventional cytology.2 
However, more false positive results were found with 
liquid based cytology, leading to a lower positive 
predictive value. The observational study by Davey 
and colleagues compared the accuracy of the automated 
ThinPrep imaging system to that of conventional 
cytology, using split sample pairs (the ThinPrep sample 
was obtained after the conventional one in a single 
collection).3 The ThinPrep Imager detected 1.29 more 
cases of histological high grade squamous disease per 
1000 women screened than conventional cytology, 
where cervical intraepithelial neoplasia grade 1 was the 
threshold for referral to colposcopy.
What do these results add to what is already known? 
Several manufacturers have developed liquid based 
cytology systems. The literature evaluating them is 
extensive and varied. Most are observational studies, 
either split sample studies or studies comparing outcome 
with previous outcomes at the same laboratory.4 Several 
national screening programmes and bodies such as 
the Food and Drug Administration have evaluated the 
evidence for liquid based cytology and come to different 
conclusions,5 6 although most evaluations have led to 
implementation. Of the few randomised controlled trials, 
those considered to be of high quality have tended to show 
no difference in sensitivity with liquid based cytology.7 
This wealth of conflicting data presents difficulties for 
screening programmes worldwide, trying to make deci-
sions on implementation in their own setting. Cervical 
screening has had varying levels of success in different 
countries. Rates of inadequate conventional smears vary 
from 9.5% in the United Kingdom to <1% elsewhere. 
Detection rates for abnormalities vary as well (even after 
differences in terminology are taken into account) and 
are influenced by sensitivity of screening, incidence of 
disease in the population, coverage of the population, 
age of starting screening, and screening interval—all fac-
tors that vary between countries. The UK has one of 
the highest sensitivities for detecting abnormality in a 
single conventional smear,8 one of the longest screening 
intervals (three or five years, depending on age), and 
high population coverage (over 80%). In other countries 
women may have smears taken every six months, and 
screening every 12-24 months is common. The UK has 
rigorous training and quality assurance and is the only 
country with a policy of rapidly rescreening 100% of 
negative and inadequate samples.
These variables mean that results of the most rigor-
ous study in one setting may not be directly applicable 
in another. Factors such as training of laboratory staff 
and the people who take samples, which may have a 
major effect, have been overlooked in several otherwise 
well designed trials. The manufacturers of liquid based 
cytology systems have mandatory training courses, but 
in the UK a much more lengthy and controlled training 
process is undertaken by training centres approved by 
the NHS cervical screening programme. Trainers in the 
UK have noted that performance improves during and 
after training, suggesting that sensitivity will be increased, 
but this has not been formally evaluated. The quality 
and duration of training specific to liquid based cytology 
may have an impact on detection rate, and this could 
contribute to the differing outcomes in reported studies.
The imager study by Davey3 is exciting because a sig-
nificant increase in sensitivity has been robustly shown, 
and the authors also found a dramatic increase in screen-
ing productivity (the number of slides screened per hour 
by a single member of staff).9 However, this must be 
interpreted with caution, because the outcome could 
be different elsewhere. Controlled trials of automated 
systems compared with liquid based cytology alone are 
under way in other national settings.10
Introduction of liquid based cytology to the UK will 
be complete during 2008. This follows an evaluation 
of the available evidence by the National Institute of 
Health and Clinical Excellence, which concluded that 
liquid based cytology was as sensitive as conventional 
cytology, and commissioned an implementation pilot.11 
Increased sensitivity was not the aim of implementing 
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liquid based cytology in the UK, but in laboratories 
that have converted to liquid based cytology, specificity 
has been maintained,12 and detection rate may have 
increased.13 The desired end points in the UK—to reduce 
the rate of inadequate samples and increase screening 
capacity—have been achieved, and at least some of the 
additional cost of liquid based cytology has been offset 
by fewer repeat tests. Liquid based cytology also gives a 
platform for human papillomavirus testing, automation, 
and other new technologies, and is popular with staff. 
Women benefit from faster reports and less anxiety.
Is liquid based cytology superior to conventional cytol-
ogy? The answer is yes, but sensitivity is not the reason 
for this superiority, or at least not the only one. The 
addition of automation may make liquid based cytology 
even better.
1	 Peto	J,	Gilham	C,	Fletcher	O,	Mathews	FE.	The	cervical	cancer	epidemic	
that	screening	has	prevented	in	the	UK.	Lancet	2004;364:249-56.
2	 Ronco	G,	Cuzick	J,	Pierotti	P,	Cariaggi	MP,	Palma	PD,	Naldoni	C,	et	
al.	Accuracy	of	liquid	based	cytology	versus	conventional	cytology:	
overall	results	of	the	new	technologies	for	cervical	screening	(NTCC)	
randomised	controlled	trial.	BMJ	2007;335:28-31.
3	 Davey	E,	Irwig	L,	Macaskill	P,	D’Assuncoa	J,	Richards	A,	Farnsworth	A.	
Accuracy	of	reading	liquid	based	cytology	slides	using	the	ThinPrep	
Imager	compared	with	conventional	cytology:	prospective	study.	BMJ	
2007;335:31-5.
The future role of the Department of health
Will the new health secretary translate �olitical rhetoric into reality  
for the nHs?
Among the many papers competing for the attention of 
Alan Johnson, the new secretary of state for health, the 
one that calls out for priority is the report of a Cabinet 
Office team on the “capability” of the Department of 
Health.1 The report, one of a series of reviews ranging 
across Whitehall, is highly critical. The DH is not alone 
in attracting criticism; unsurprisingly the review of the 
Home Office was more scathing still, and no government 
department has emerged from the reviews as a flawless 
instrument for framing and executing ministerial 
policy. But the timing of the report’s publication poses 
a challenge for Mr Johnson as he takes over as health 
secretary. The challenge is to decide just what kind of 
competence he wants his department to develop, and in 
turn what the department’s role should be.
In a foreword to the capability review, the trio of 
officials at the top of the department—the permanent 
secretary, the NHS chief executive, and the chief medical 
officer—welcome its findings, inasmuch as these will add 
“focus and momentum” to what they are doing already. 
Two of the three are relatively new to their posts and may 
well welcome the extra leverage the report gives them 
in introducing change. And change is clearly needed. 
The following selection conveys the key points. Morale 
within the DH as well as within the NHS is low: “the 
pace at which change has been implemented has led to 
a sense of disenfranchisement among staff and delivery 
partners,” the report argues. The quality of briefing 
to ministers has diminished in some areas. Further, 
“policies tend to be developed in organizational silos 
and cross-boundary integration issues are not routinely 
thought through” with the result that “tensions between 
individual well-intended policies” emerge during 
implementation. Sufficient emphasis is not always placed 
on planning how policy will be implemented. And “there 
is a need for more consistent engagement between the 
Department and front-line staff.”
Some of the flaws diagnosed by the review have a long 
history: many organisational permutations have tried to 
overcome the problem of policy silos.2 But others reflect 
the DH’s more recent transformation from a traditional 
civil service department into a new managerial model 
“focused on delivery of political objectives rather than 
policy or risk analysis, weak in policy research capacity 
but willing to respond to central direction,” as a recent 
study argues.3 As of May 2006, only one of the top 32 
officials in the DH was a career civil servant, whereas 
18 came from the NHS and six from the private sector. 
The shift has been from those who saw their role as 
being to save ministers from themselves, to those who 
saw it as being to deliver results. If the pathology of the 
former approach was conservative obstructionism, that 
of the latter was a readiness to run with even the silliest 
ministerial initiative.
Other factors, too, have been at work. The staff of 
the DH has been cut by half. Institutional memory 
has suffered as the knowledge of what did or did not 
work in the past has been dispersed; policy work has 
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Advising patients on dealing with acute chest pain
Instr�ctions abo�t �sing Gtn and when to call an amb�lance need to be clearer
How long people with chest pain should wait before 
calling an ambulance is a question familiar to general 
practitioners and emergency doctors. The answer is 
complicated by the use of sublingual nitrate sprays, 
which promptly relieve the pain of stable angina.1 
Ideally, patients would be able to distinguish stable 
angina from a potentially life threatening acute coro-
nary syndrome, but in reality they do not. Therefore 
the decision about when to call an ambulance needs 
to balance between an overly cautious strategy that 
could overburden emergency medical services and 
one where delayed action leads to higher morbidity 
and mortality. The balance is difficult to find because 
international guidance indicates that consensus has not 
been reached, even among cardiologists.2-4
The British Heart Foundation advises patients with 
known ischaemic heart disease that chest pain that 
lasts more than 15 minutes is probably a heart attack.2 
Within this time patients are advised to use their glyceryl 
trinitrate (GTN) spray three times at five minute intervals 
before calling an ambulance. Yet a recent British Heart 
Foundation campaign advises members of the general 
public with potential “de novo” chest pain (a lower risk 
population) that “A chest pain is your body saying call 
999. Doubt kills—call 999 immediately.” 
Campaigns aimed at the general population have 
been unsuccessful in reducing mortality from acute 
coronary syndromes.5 6 However, no studies have 
examined the effect solely in people at high risk—those 
with an established diagnosis of ischaemic heart disease 
and those with established cardiovascular disease or 
risk factors for cardiovascular complications7—and 
the potential of sublingual nitrates to prompt a rapid, 
appropriate response (in turn reducing mortality and 
morbidity associated with late presentation). 
The European Society of Cardiology does not offer 
precise guidance; it simply advises “carefully instructing 
patients on the use of short acting nitroglycerin.”5 The 
recommendations of the American College of Cardiology 
and American Heart Association were previously in line 
with the British Heart Foundation. However, updated 
guidelines in 2004 encouraged patients with symptoms 
suggesting ST elevation myocardial infarction (STEMI) 
to contact emergency medical services earlier. They now 
recommend “one GTN spray and 5 minutes” before 
calling an ambulance.6
Manufacturers of nitrate sprays also give varying and 
sometimes non-specific instructions regarding the dose, 
such as “No more than three metered doses at any one 
time and a minimum of 15 minutes between consecutive 
treatments.” Therefore, the onus is on the prescribing 
doctor to guide the patient.
The evidence for early presentation and treatment of 
STEMI has long been established. Necrosis of viable 
myocardium predominantly occurs between 30 to 
90 minutes after coronary artery occlusion. This has 
formed the basis of “the golden hour” during which 
prompt reperfusion strategies (thrombolysis or primary 
angioplasty) prevent extensive myocardial necrosis 
that leads to left ventricular dysfunction and worse 
prognosis. Even before angioplasty became widely used, 
thrombolysis within the first hour cut deaths by half.8 
This led to the advent of prehospital thrombolysis and 
“call to needle” targets, which are generally being met.
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been farmed out to consultants, with mixed results. 
But central to the changes has been the emphasis 
on delivery. The DH scores well on delivery in the 
capability review, with the usual litany of waiting 
time and other targets achieved. The emphasis on 
delivery—and the accompanying culture of target 
setting—has meant developing the ability of central 
government to monitor and, if need be, intervene in 
local performance.4 The DH has done this in spades. 
But now, as the review points out, “The Department 
needs to lead the next stage of transition in the NHS 
from top-down performance management to locally 
driven healthcare systems.”
Will the new secretary of state accept the logic of 
“locally driven healthcare systems” and accept diversity 
in the pursuit of national policies? If he does, the DH 
can develop the competencies required for a more 
policy oriented role, so avoiding a repetition of recent 
policy fiascos, such as new medical contracts which 
managed to attract widespread criticism of excessive 
generosity—of paying more for less work—while still 
leaving the profession in a state of tetchy unhappiness. 
The point remains relevant whatever happens about 
the future governance of the NHS.
The case for some kind of independent board for the 
NHS combines two distinct arguments.5 The first is that 
such a board would insulate the NHS from day to day 
political interference; the second is that it would insulate 
the NHS from intrusive central direction. The two are 
not necessarily linked: an independent board could be 
just as directive as any government department. So the 
crucial question is whether Mr Johnson will translate the 
political rhetoric about locally driven health care and the 
empowerment of NHS professionals into reality.
1	 Cabinet	Office.	Capability review of the Department of Health.  London:	
Cabinet	Office,	June	2007.	www.civilservice.gov.uk/reform/
capability_reviews/publications/pdf/Capability_Review_DfH.pdf
2	 Day	P,	Klein	R	Steering but not rowing? The transformation of the 
Department of Health.	Bristol:	Policy	Press,	1997.
3	 Greer	SL,	Jarman	H.	The Department of Health and the civil service: from 
Whitehall to department of delivery to where? London:	Nuffield	Trust,	
2007.	www.nuffieldtrust.org.uk/ecomm/files/DHCSW%20(final).pdf
4	 Barber	M.	Instruction to deliver: Tony Blair, public services and the 
challenge of achieving targets.	London:	Politicos,	2007.
5	 Edwards	B.	An independent NHS: a review of the options.	London:	
Nuffield	Trust,	2007.	www.nuffieldtrust.org.uk/ecomm/files/
IndependentNHS.pdf
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Three randomised controlled trials consistently 
show that medically performed male circumcision 
can reduce the acquisition of HIV infection in 
men by at least 50%.1-3 In east Africa and southern 
Africa—where rates of new HIV infections are high 
and circumcision rates are low—modelling studies 
estimate that circumcision could reduce the incidence 
of HIV in men by 50-60%.4 5 Clearly, the size of this 
effect would be determined by uptake. If uptake 
were 100%, an estimated 2 million new infections 
and 0.3 million deaths in sub-Saharan Africa would 
be averted over 10 years, and up to 5.7 million new 
infections would be averted over 20 years.6 In a 
setting like Orange Farm in South Africa where one 
of the trials was performed,1 a 50% uptake of male 
circumcision could avert 32 000-53 000 new infections 
over 20 years. Conclusions about the effect of male 
circumcision on the acquisition of HIV in women are 
awaiting the completion of a trial in Rakai, which is 
expected in 2008.7
Quarraisha Abdool Karim 
associate scientific director 
Centre for the aIDs programme of 
research in so�th africa (CaprIsa), 
Doris D�ke Medical research 
Instit�te, nelson r Mandela school 
of Medicine, university of KwaZ�l�-
natal, Congella 4013, so�th africa 
abdoolq2@ukzn.ac.za
Competing interests: none  declared.
Provenance and peer review:  
Commissioned; not externally  
�eer reviewed.
BMJ 2007;335:4-5
doi:10.1136/bmj.39245.491169.BE
Prevention of hIV by male circumcision  
Effective b�t integration with existing sex�al health services remains the 
biggest challenge
If the patient has a cardiac arrest out of hospital, early 
attention from a paramedical team with a defibrillator 
is life saving, but the chance of successful defibrillation 
declines 7-10% each minute after cardiac arrest.9 One 
early study of out of hospital cardiac arrest showed that 
the median time from onset of symptoms to cardiac 
arrest was 10 minutes.10 Clearly, waiting 15 minutes, as 
the British Heart Foundation suggests,2 will be too long 
for some patients.
Recent data on sudden cardiac death do not confirm 
the early series; the symptoms were present for a median 
of 30 minutes before ventricular fibrillation started.11 
However, the data do confirm that most sudden cardiac 
deaths occur in patients with known cardiac disease, at 
home, and in the presence of relatives. This reaffirms the 
importance of clear and precise education for patients 
and relatives.
Most acute coronary syndromes occur in people 
already known to have ischaemic heart disease or to 
be at high risk. In this group the risk of subsequent 
myocardial infarction or death is 5-7 times higher than 
in the general population, and at least 70% of deaths 
from coronary heart disease occur in people who 
have had previous manifestations of cardiovascular 
disease.12 However, recent data have shown that 40% 
of the general population would not immediately call 
an ambulance during a suspected myocardial infarction, 
and the greatest delays in calling 999 are in people at 
high risk.13 The obvious implication is that people at high 
risk are not receiving clear, effective guidance despite 
receiving care from a doctor at some stage.
The advent of rapid access chest pain clinics, patient 
information leaflets, and cardiac rehabilitation clinics 
may have made the medical community complacent 
about face to face doctor-patient counselling. However, 
any clinician faced with a patient with existing ischaemic 
heart disease should be able to give clear and precise 
instructions about when to call an ambulance.
On the basis of the pharmacodynamics of sublingual 
nitrates and the benefit of early presentation, we advise 
patients with known ischaemic heart disease or at high 
risk of myocardial infarction to carry a GTN spray at 
all times and, should they develop acute chest pain, to 
take two metered doses (800 µg) immediately. If the pain 
persists at five minutes they should call an ambulance. 
They should not waste time by first calling a friend 
or relative and should not drive themselves to the 
emergency department.14 15 Patients and their relatives 
should also be taught how to recognise high risk features 
of chest pain, such as increasing frequency and severity 
of attacks (unstable angina), and autonomic features 
(common in STEMI).
1	 Parker	J,	Parker	J.	Drug	therapy:	nitrate	therapy	for	stable	angina.	N Engl 
J Med	1998;338:520-31.
2	 Angina–Heart	Information	Series	Number	6.	British	Heart	Foundation	
April	2006:	5-7	(www.bhf.org.uk/publications.aspx)	
3	 Fox	K,	Garcia	MA,	Ardissino	D,	Buszman P, Camici PG, Crea F.	Guidelines	
on	the	management	of	stable	angina	pectoris:	executive	summary:	
the	Task	Force	on	the	Management	of	Stable	Angina	Pectoris	of	the	
European	Society	of	Cardiology.	Eur Heart J	2006;2:1341-81.
4	 Antman	EM,	Anbe	DT,	Armstrong	PW,	Bates ER, Green LA, Hand M.	
ACC/AHA	guidelines	for	the	management	of	patients	with	ST-elevation	
myocardial	infarction—executive	summary:	a	report	of	the	American	
College	of	Cardiology/American	Heart	Association	Task	Force	on	
Practice	Guideline.	Circulation	2004;110:588-636.
5	 Bhlom	M,	Herlitz	J,	Hartford	M,	Karlson	BW,	Risenfors	M,	Luepker	
RV.	Consequences	of	a	media	campaign	focusing	on	delay	in	acute	
myocardial	infarction.	Am J Cardiol	1992;69:411-	3.
6	 Luepker	RV,	Raczynski	JM,	Osganian	S,	Goldberg	RJ,	Finnegan	JR,	
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emergency	medical	service	use	in	acute	coronary	heart	disease:	
the	rapid	early	action	for	coronary	treatment	(REACT)	trial.	JAMA	
2000;284:60-7.
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calculators.	2004.	www.bhsoc.org/Cardiovascular_Risk_Charts_
and_Calculators.stm
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hour.	Lancet	1996;348:771-5.
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Emerg Med 1993;22:1652-8.
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infarction.	Excerpta Medica	1972;1:95-106.
11	 Muller	D,	Agrawal	R,	Arntz	HR.	How	sudden	is	sudden	cardiac	death?	
Circulation	2006;114:1146-50.
12	 Dracup	K,	Alonzo	A,	Atkins	JM,	Bennett	NM,	Braslow	A,	Clark	LT.	The	
physician’s	role	in	minimising	prehospital	delay	in	patients	at	high	risk	
for	acute	myocardial	infarction:	recommendations	from	the	national	
heart	attack	alert	programme.	Ann Intern Med	1997;126:645-51.
13	 YouGov	survey,	November	2006.
14	 Faxon	D,	Lenfant	C.	Timing	is	everything:	motivating	patients	to	call		
9-1-1	at	onset	of	acute	myocardial	infarction.		
Circulation	2001;104:1210-1.
15	 Hutchings	C,	Mann	C,	Daya	M,	Jui	J,	Goldberg	R,	Cooper	L.	Patients	with	
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Countries face many challenges as they consider 
policies on circumcision for preventing HIV, 
especially as a surgical intervention in healthy men 
for preventing an infectious disease is a new paradigm 
in public health.
The United Nations AIDS/World Health 
Organization guidance on scaling up male circumcision 
is a useful starting point at a country level.4 It advises 
that male circumcision should be included as part of 
a comprehensive package of HIV prevention; health 
services in developing countries should be strengthened 
to provide high quality circumcision services; and that 
circumcision should be targeted in populations with low 
circumcision rates and high HIV prevalence at no cost 
to the client.4
Uptake will be socially complex as circumcision 
involves aesthetic changes to the penis that impact 
on perceptions of masculinity, religious practices, and 
rites of passage for boys to manhood in many African 
cultures. Also, an intervention where healthy men 
undergo an irreversible surgical procedure that carries 
about a 10% complication rate makes informed consent 
for the procedure extremely important. The consent 
process will have the added benefit of providing an 
opportunity for integrating counselling on safer sex 
practices and of enhancing strategies for HIV risk 
reduction at the individual level.
How to integrate this intervention into existing 
services is a major challenge in these settings. Health 
services for people who would benefit most from 
this intervention are already under strain from years 
of underfunding and neglect, as well as the impact 
of the AIDS epidemic. To offer safe circumcision on 
the scale needed to affect the transmission of HIV 
within communities, investment is needed for training 
healthcare workers; developing surgical facilities; 
obtaining surgical supplies, especially suture material; 
and sterilising surgical equipment.
In addition, preliminary data from the ongoing trial 
in Rakai suggest an excess risk of HIV transmission in 
women from circumcised men who are infected with 
HIV, perhaps because sexual intercourse is resumed 
before the wound has fully healed. Therefore, until 
more definitive data are available, men should be 
tested for HIV before circumcision, and voluntary 
testing and counselling services need to be available. 
Increased uptake of circumcision may cause a shift in 
the social norm, which might result in stigmatisation of 
uncircumcised men, who may be seen as less “safe.”
A further challenge will be deciding which healthcare 
providers should be allowed to perform surgery given 
the dire shortage of trained medical personnel in 
the developing world. One question is whether only 
doctors and clinical assistants will be allowed to perform 
circumcisions, or whether nurses—who are often the only 
healthcare providers in rural communities—will also be 
allowed to perform them. Another question is whether 
health services will work with traditional circumcisers 
(indigenous practitioners responsible for rites of passage 
into adulthood or performing circumcision for religious 
or cultural reasons). Complications of the surgery, 
principally sepsis, will place an additional burden on 
healthcare and referral systems.
What impact will implementation of circumcision 
have on the public sector health service? Many 
countries of southern Africa—where health services are 
underdeveloped and overburdened—will have to rethink 
how nurses provide antenatal care, contraception 
services, childhood immunisations, and other essential 
healthcare services. The experience in rolling out 
antiretroviral therapy can give an idea of the impact on 
health services in resource poor settings.
While resources from the President’s Emergency Plan 
for AIDS Relief and the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria have successfully secured 
antiretroviral drugs and created the impetus for the 
rollout of AIDS care, the limited numbers of healthcare 
personnel have no spare capacity. Providing circumcision 
must not compromise the provision of other important 
components of the routine health service. Careful thought 
needs to be given to whether a dedicated circumcision 
programme is warranted and, if so, whether it would be 
sustainable beyond donor funding.
Young, healthy men are not frequent users of health 
facilities, except for sexually transmitted diseases. 
Programmes that integrate safe male circumcision 
with other sexual and reproductive health services will 
enhance access to health services for young men, offer 
HIV testing and counselling, and provide behavioural 
counselling, treatment for sexually transmitted diseases, 
health education, and interventions to protect women 
from violence.
Further research will need to define how to initiate 
such programmes, test different ways of providing 
circumcision, develop training programmes, and the 
mechanisms of supplying the necessary equipment. 
Important considerations are what factors contribute to 
uptake, how to monitor and deal with adverse events, 
and the perceptions and sexual behaviour of individuals 
and communities.
Given the potential benefit of male circumcision, the 
UNAIDS/WHO guidance should be implemented in 
the context of the challenges described above.
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NhS research ethics committees
still need more common sense and less b�rea�cracy
National Health Service research ethics committees 
exist to ensure that research performed within the 
NHS complies with recognised ethical standards and 
to protect the rights, safety, and dignity of all actual or 
potential participants. In the past decade the operation 
of research ethics committees has come under, and con-
tinues to come under, close scrutiny. Researchers now 
consider the process of acquiring ethical approval to be 
so onerous that it is compromising clinical research.1-3 
Medical educators also think that the process is too 
unwieldy to allow undergraduate students to acquire 
research experience,4 an essential learning outcome 
required by the General Medical Council.5
To understand why such dissatisfaction has arisen we 
need to go back to the early 2000s, when the Central 
Office for Research Ethics Committees (COREC) 
was established and the Department of Health issued 
the Research Governance Framework for Health and Social 
Care.6 The implementation in 2001 of the European 
Union Directive 2001/20/EC (the clinical trials 
directive) forced changes in the system, leading to the 
introduction of a single application form for multisite 
applications and a rule that research ethics committees 
had to respond to applications within 60 days. These 
changes substantially helped those involved in complex, 
usually multicentre, studies.
In response to the growing discontent expressed 
by researchers about the complexity of the research 
governance process, the Department of Health 
established an advisory group to review the operation 
of research ethics committees.7 Its report confirmed 
that researchers still perceived the process as too 
bureaucratic, and its conclusions were sensible and long 
overdue. These included an immediate recommendation 
that research ethics committees and research and 
development departments within trusts should make 
multiple use of information supplied only once. The 
review group considered that some research—such as 
surveys, service evaluation, and research on NHS staff—
did not require formal ethical review and proposed the 
creation of scientific officers who would act in a triage 
capacity to provide a preliminary assessment of such 
applications. The response of the Central Office for 
Research Ethics Committees, Building on Improvement: 
Implementing the Recommendation of the Report of the Ad 
Hoc Advisory Group on the Operation of NHS Research Ethics 
Committees, was disseminated for consultation last year.8 
The recommendations of the advisory group report7 
have largely been translated into practical and feasible 
solutions. “Scientific officers” become research ethics 
advisers, to exist at both a national and local level. Their 
job will be to provide a rapid review of studies with no 
untoward ethical implications, to triage applications 
that require full ethics committee consideration, and 
to provide educational support to applicants. The 
central committee acknowledged the need for further 
improvements in the application form (it is still long, 
although the latest version has an early filter question to 
ensure only relevant questions are activated). Was this 
eventually the spoonful of sugar to make the process of 
ethical approval more palatable for researchers?
Maybe, but if we look more closely at how the 
recommendations will be implemented, is there still 
the potential for sound intentions to be undermined 
by disproportionate bureaucracy? The research 
ethics advisers need to be very experienced: the 
report recommends experience as a chair of an ethics 
committee. The proposed triage procedure will need 
piloting, and training requirements will need to be 
identified. Several levels of filter are suggested from 
initial review by a coordinator, through to a senior 
coordinator, then the research ethics adviser, and if 
necessary, the research ethics committee. Although 
the report acknowledges that the large volume of 
undergraduate student applications will not present 
substantial ethical concerns, it rejects the need for a 
separate application process or separate system of 
committees for student projects—recommendations 
that were suggested in the Doyle report,9 made in 
2004 by a national interprofessional working group. For 
postgraduate students this seems eminently appropriate, 
but is this a missed opportunity to streamline 
undergraduate applications? In the consultation 
process after release of the recent central committee 
recommendations,8 a fast track system for approving 
low risk studies was wholeheartedly supported by 
patients, in recognition that this would allow research 
ethics committees to concentrate their resources more 
appropriately. In a recent study exploring the impact 
of research governance on medical students’ ability 
to gain an understanding of research methodology, a 
fast track application process and the introduction of 
a specific shortened form were considered the most 
important strategies to facilitate this aim.4 Failure to 
deal with the problem of student research will make it 
more difficult to ensure coverage of research within the 
undergraduate curriculum as required by the GMC.5 
Such a lack of academic exposure at undergraduate 
level will only contribute to the already critical shortage 
of doctors entering academic medicine.10 11
Both medical researchers and teachers support the 
principles of research governance.4 The proposed 
changes to research governance to allow certain 
research, such as surveys and studies involving NHS 
staff, to be exempt from research ethics committee 
review8 and may rekindle medical teachers’ interest 
in helping undergraduate students gain research expe-
rience. Building on Improvement provides a longed for 
opportunity to make research more accessible to all 
researchers; let us hope it is not too little too late for 
undergraduate research. 
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